Compare OBT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBT | CLLS |
|---|---|---|
| Founded | 1892 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 457.5M | 394.4M |
| IPO Year | 2021 | 2014 |
| Metric | OBT | CLLS |
|---|---|---|
| Price | $38.34 | $2.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $36.00 | $8.33 |
| AVG Volume (30 Days) | ★ 52.2K | 15.2K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.12% | N/A |
| EPS Growth | ★ 34.82 | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.27 | N/A |
| Revenue Next Year | $7.99 | $0.98 |
| P/E Ratio | $45.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.25 | $2.35 |
| 52 Week High | $40.10 | $5.48 |
| Indicator | OBT | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 56.89 | 42.56 |
| Support Level | $35.90 | $2.65 |
| Resistance Level | $38.53 | $2.98 |
| Average True Range (ATR) | 1.03 | 0.16 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 74.17 | 56.25 |
Orange County Bancorp Inc is a community bank holding company providing commercial and consumer banking services to individuals, small businesses, and local governments. It operates through two segments: Banking and Wealth Management. The Banking segment, the primary revenue driver, offers loans such as commercial real estate, construction, commercial & industrial, multifamily, and residential mortgages, along with services like cash management, escrow, deposits, ATMs, and digital banking. The Wealth Management segment provides investment management, trust services (trustee, administrator, custodian), and financial planning and advisory services to individuals and institutions.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.